Ignet

Gene Information

Gene symbol: F8

Gene name: coagulation factor VIII, procoagulant component

HGNC ID: 3546

Synonyms: FVIII, DXS1253E, HEMA

Related Genes

#	Gene Symbol	Number of hits
1	ABO	1 hits
2	ALB	1 hits
3	C20orf181	1 hits
4	F2	1 hits
5	F7	1 hits
6	F9	1 hits
7	IAPP	1 hits
8	INS	1 hits
9	PF4	1 hits
10	PLAT	1 hits
11	PPBP	1 hits
12	REN	1 hits
13	SERPINE1	1 hits
14	SERPINE2	1 hits
15	TFPI	1 hits
16	VWF	1 hits

Related Sentences

#	PMID	Sentence
1	1081963	In 18 insulin-dependent diabetics (6 without retinopathy, 6 with proliferative retinopathy and 6 with proliferative retinopathy treated by hypophysectomy) matched for age and duration of diabetics, in vitro haemostasis was studied using ADP induced platelet aggregation, ristocetin induced platelet aggregation which allows von Willebrand factor (VIII VWF) assay, and determination of antihemophilic factor procoagulant activity (VII AHF).
2	1081963	High level of plasma VII VWF was observed in diabetics with proliferative retinopathy while the VII AHF level was within normal limits.
3	1081963	In 18 insulin-dependent diabetics (6 without retinopathy, 6 with proliferative retinopathy and 6 with proliferative retinopathy treated by hypophysectomy) matched for age and duration of diabetics, in vitro haemostasis was studied using ADP induced platelet aggregation, ristocetin induced platelet aggregation which allows von Willebrand factor (VIII VWF) assay, and determination of antihemophilic factor procoagulant activity (VII AHF).
4	1081963	High level of plasma VII VWF was observed in diabetics with proliferative retinopathy while the VII AHF level was within normal limits.
5	3116705	Factor VIII (FVIII) and plasminogen activator activity (PAA) rise during hypoglycaemia, and this might contribute to the vascular complications of diabetes.
6	3116705	FVIII coagulant activity (FVIII:C) rose from 0.75 to 1.09 IU/ml (p less than 0.01) and the ristocetin co-factor (FVIIIR:Co) and von Willebrand factor antigen (vWF:Ag) showed similar responses.
7	3116705	Despite this, plasma aVP, FVIII:C, FVIIIR:Co, vWF:Ag and PAA remained unchanged.
8	3116705	This study indicates that the marked changes in FVIII, vWF and PAA concentrations which accompany hypoglycaemia depend on low blood glucose and not raised plasma insulin.
9	3116705	Factor VIII (FVIII) and plasminogen activator activity (PAA) rise during hypoglycaemia, and this might contribute to the vascular complications of diabetes.
10	3116705	FVIII coagulant activity (FVIII:C) rose from 0.75 to 1.09 IU/ml (p less than 0.01) and the ristocetin co-factor (FVIIIR:Co) and von Willebrand factor antigen (vWF:Ag) showed similar responses.
11	3116705	Despite this, plasma aVP, FVIII:C, FVIIIR:Co, vWF:Ag and PAA remained unchanged.
12	3116705	This study indicates that the marked changes in FVIII, vWF and PAA concentrations which accompany hypoglycaemia depend on low blood glucose and not raised plasma insulin.
13	3116705	Factor VIII (FVIII) and plasminogen activator activity (PAA) rise during hypoglycaemia, and this might contribute to the vascular complications of diabetes.
14	3116705	FVIII coagulant activity (FVIII:C) rose from 0.75 to 1.09 IU/ml (p less than 0.01) and the ristocetin co-factor (FVIIIR:Co) and von Willebrand factor antigen (vWF:Ag) showed similar responses.
15	3116705	Despite this, plasma aVP, FVIII:C, FVIIIR:Co, vWF:Ag and PAA remained unchanged.
16	3116705	This study indicates that the marked changes in FVIII, vWF and PAA concentrations which accompany hypoglycaemia depend on low blood glucose and not raised plasma insulin.
17	3116705	Factor VIII (FVIII) and plasminogen activator activity (PAA) rise during hypoglycaemia, and this might contribute to the vascular complications of diabetes.
18	3116705	FVIII coagulant activity (FVIII:C) rose from 0.75 to 1.09 IU/ml (p less than 0.01) and the ristocetin co-factor (FVIIIR:Co) and von Willebrand factor antigen (vWF:Ag) showed similar responses.
19	3116705	Despite this, plasma aVP, FVIII:C, FVIIIR:Co, vWF:Ag and PAA remained unchanged.
20	3116705	This study indicates that the marked changes in FVIII, vWF and PAA concentrations which accompany hypoglycaemia depend on low blood glucose and not raised plasma insulin.
21	3135635	Venous blood samples were taken at the beginning and end of each hour after the run-in period for assays of factor VIII coagulant activity (FVIII:C), von Willebrand factor antigen (vWF:Ag), ristocetin co-factor (FVIIIR:Co), activated partial thromboplastin time (APTT) and vasopressin (aVP).
22	3922075	In this longitudinal study we measured beta-TG, PF4, fibrinolytic activity (extrinsic and euglobulin fraction), fibrinogen, FVIII RAg and FVIII Rcof before and after i.v.
23	3922075	No significant differences related to metabolic control were found for beta-TG, PF4, FPA and fibrinogen.
24	7578890	Smaller studies have identified increases in FVIII/vWF in association with acute stroke and raised levels of tissue plasminogen activator.
25	8232694	These haemodynamic responses are associated with increments in the plasma levels of renin, noradrenaline (NA), clotting factor VIII (FVIII:C), von Willebrand factor (vWF:ag), and tissue-type plasminogen activator (t-PA), and a fall in the plasma level of plasminogen activator inhibitor (PAI).
26	8232694	The responses of vWF:ag and t-PA to venous occlusion in the patients with NDI were similar to those in 5 healthy volunteers, which indicates that in NDI the endothelial release of both vWF:ag and t-PA is normal.
27	8232694	We conclude that DDAVP causes its effects on heart rate and blood pressure, and on the plasma levels of renin, noradrenaline, FVIII:C, vWF:ag, and t-PA through V2-receptor stimulation.
28	8232694	These haemodynamic responses are associated with increments in the plasma levels of renin, noradrenaline (NA), clotting factor VIII (FVIII:C), von Willebrand factor (vWF:ag), and tissue-type plasminogen activator (t-PA), and a fall in the plasma level of plasminogen activator inhibitor (PAI).
29	8232694	The responses of vWF:ag and t-PA to venous occlusion in the patients with NDI were similar to those in 5 healthy volunteers, which indicates that in NDI the endothelial release of both vWF:ag and t-PA is normal.
30	8232694	We conclude that DDAVP causes its effects on heart rate and blood pressure, and on the plasma levels of renin, noradrenaline, FVIII:C, vWF:ag, and t-PA through V2-receptor stimulation.
31	8329566	Accordingly, we investigated the effects of increasing FVIII:C levels on coagulation in vitro using a computer-assisted measurement of thrombin activity.
32	8329566	Increasing FV concentrations resulted in an additive effect with high FVIII:C levels on the rate of thrombin generation.
33	8329566	The results showed that increasing plasma FVIII:C and FV concentrations accelerate rate of generation of thrombin activity independently, and in an additive manner.
34	8329566	Accordingly, we investigated the effects of increasing FVIII:C levels on coagulation in vitro using a computer-assisted measurement of thrombin activity.
35	8329566	Increasing FV concentrations resulted in an additive effect with high FVIII:C levels on the rate of thrombin generation.
36	8329566	The results showed that increasing plasma FVIII:C and FV concentrations accelerate rate of generation of thrombin activity independently, and in an additive manner.
37	8329566	Accordingly, we investigated the effects of increasing FVIII:C levels on coagulation in vitro using a computer-assisted measurement of thrombin activity.
38	8329566	Increasing FV concentrations resulted in an additive effect with high FVIII:C levels on the rate of thrombin generation.
39	8329566	The results showed that increasing plasma FVIII:C and FV concentrations accelerate rate of generation of thrombin activity independently, and in an additive manner.
40	8362378	In addition, APTT, factor VIII and thrombin-antithrombin III (TAT) complex levels were measured.
41	8362378	A greater increase in FVIII:C than vWF levels occurred in controls [0.2 (0.1); 0.1 (0.1) IU ml-1; (p = 0.005)] and patients [0.3 (0.4); 0.2 (0.1) IU ml-1; (p = 0.032)].
42	8403679	In cerebral thrombosis at the chronic stage, the coagulation factor VIII (FVIII), von Willebrand factor (vWF), and platelet factor IV were elevated significantly as compared with age-matched controls.
43	8403679	Diabetics with neuropathy showed significantly elevated FVIII and vWF in comparison with diabetics without neuropathy and controls.
44	8403679	The patients with vasculitic neuropathy exhibited significantly elevated FVIII, vWF and fibrin/fibrinogen degradation products (FDP).
45	8403679	The present study demonstrated that FVIII and vWF are useful parameters for the evaluation of the extent of vascular involvement in angiopathies of different etiologies.
46	8403679	In cerebral thrombosis at the chronic stage, the coagulation factor VIII (FVIII), von Willebrand factor (vWF), and platelet factor IV were elevated significantly as compared with age-matched controls.
47	8403679	Diabetics with neuropathy showed significantly elevated FVIII and vWF in comparison with diabetics without neuropathy and controls.
48	8403679	The patients with vasculitic neuropathy exhibited significantly elevated FVIII, vWF and fibrin/fibrinogen degradation products (FDP).
49	8403679	The present study demonstrated that FVIII and vWF are useful parameters for the evaluation of the extent of vascular involvement in angiopathies of different etiologies.
50	8403679	In cerebral thrombosis at the chronic stage, the coagulation factor VIII (FVIII), von Willebrand factor (vWF), and platelet factor IV were elevated significantly as compared with age-matched controls.
51	8403679	Diabetics with neuropathy showed significantly elevated FVIII and vWF in comparison with diabetics without neuropathy and controls.
52	8403679	The patients with vasculitic neuropathy exhibited significantly elevated FVIII, vWF and fibrin/fibrinogen degradation products (FDP).
53	8403679	The present study demonstrated that FVIII and vWF are useful parameters for the evaluation of the extent of vascular involvement in angiopathies of different etiologies.
54	8403679	In cerebral thrombosis at the chronic stage, the coagulation factor VIII (FVIII), von Willebrand factor (vWF), and platelet factor IV were elevated significantly as compared with age-matched controls.
55	8403679	Diabetics with neuropathy showed significantly elevated FVIII and vWF in comparison with diabetics without neuropathy and controls.
56	8403679	The patients with vasculitic neuropathy exhibited significantly elevated FVIII, vWF and fibrin/fibrinogen degradation products (FDP).
57	8403679	The present study demonstrated that FVIII and vWF are useful parameters for the evaluation of the extent of vascular involvement in angiopathies of different etiologies.
58	8508616	In all subjects and in patients, FVIII:C was related to urinary albumin excretion and creatinine clearance.
59	9024277	Autosomal recessive nephrogenic diabetes insipidus caused by an aquaporin-2 mutation.
60	9024277	Vasopressin V2 receptors, expressed from an x-chromosomal gene, are involved in antidiuresis, but also in release of coagulation factor VIII and von Willebrand factor (vWF).
61	9805643	Von Willebrand factor (vWf), a multimeric glycoprotein mainly synthesised by endothelial cells, is involved in platelet adhesion and aggregation and acts as the carrier of coagulation factor VIII in plasma.
62	9805643	Concomitant with high vWf levels, other possible mechanisms of endothelial damage include reduced synthesis or release of nitric oxide, hyperglycaemic pseudohypoxia and protein kinase-C activation, increased synthesis of proteins bearing advanced glycosylation end-products or transforming growth factor-beta (TGF-beta) activation of coagulation and inhibition of fibrinolysis.
63	10331423	Measured were plasma activated factor VII activity (FVIIa), FVII coagulant (FVIIC) activity, FVIII coagulant (FVIIIC) activity, tissue factor pathway inhibitor (TFPI) antigen, and thrombin markers; and serum glucose, insulin, and electrolytes.
64	12724002	Multivariate genetic analysis was performed using a total of 314 (107 monozygotic and 207 dizygotic) twin pairs on IR assessed by HOMA, fibrinogen, plasminogen activator inhibitor (PAI-1), tissue plasminogen activator (tPA), factor VIII (FVIII), von Willebrand factor (vWF) and factor XIII B-subunit.
65	15892651	Whilst the plasma levels of many clotting factors including fibrinogen, FVII, FVIII, FXII, FXIII b-subunit are elevated, the fibrinolytic system is relatively inhibited as a consequence of an increase in plasminogen activator inhibitor type-1 (PAI-1) levels.
66	18327551	To this end, mammalian cell engineering technologies were used to generate cell lines over-expressing several different recombinant proteins of biomedical and biotechnological interest, namely, recombinant human Amylin/IAPP for diabetes treatment, human FVIII and FIX clotting factors for hemophilia, human and bovine FSH for fertility and reproduction, and human bone repair proteins (BMPs).
67	21934489	The present study was undertaken to elucidate whether elevated levels of factor VIII (FVIII) and von Willebrand factor (vWF) in women with type 2 diabetes represent endothelial dysfunction, inflammation or an alternate mechanism.
68	21934489	Several haemostatic markers including, FVIII, vWF and fibrinogen were assessed.
69	21934489	In addition, thrombomodulin, a marker for endothelial damage, and high-sensitivity C-reactive protein (hsCRP), an inflammatory marker, were also measured.
70	21934489	The present study was undertaken to elucidate whether elevated levels of factor VIII (FVIII) and von Willebrand factor (vWF) in women with type 2 diabetes represent endothelial dysfunction, inflammation or an alternate mechanism.
71	21934489	Several haemostatic markers including, FVIII, vWF and fibrinogen were assessed.
72	21934489	In addition, thrombomodulin, a marker for endothelial damage, and high-sensitivity C-reactive protein (hsCRP), an inflammatory marker, were also measured.
73	22219226	Factor VIII (FVIII) functions as a cofactor for factor IXa in the contact coagulation pathway and circulates in a protective complex with von Willebrand factor (VWF).
74	22219226	Plasma FVIII activity is strongly influenced by environmental and genetic factors through VWF-dependent and -independent mechanisms.
75	22219226	Among covariates, age, race, diabetes, and ABO contributed 2.2%, 3.5%, 4%, and 10.7% to FVIII intersubject variation, respectively.
76	22219226	Seven VWF SNPs were associated with FVIII activity in EA subjects, but no FVIII SNPs were associated with VWF Ag.
77	22219226	Factor VIII (FVIII) functions as a cofactor for factor IXa in the contact coagulation pathway and circulates in a protective complex with von Willebrand factor (VWF).
78	22219226	Plasma FVIII activity is strongly influenced by environmental and genetic factors through VWF-dependent and -independent mechanisms.
79	22219226	Among covariates, age, race, diabetes, and ABO contributed 2.2%, 3.5%, 4%, and 10.7% to FVIII intersubject variation, respectively.
80	22219226	Seven VWF SNPs were associated with FVIII activity in EA subjects, but no FVIII SNPs were associated with VWF Ag.
81	22219226	Factor VIII (FVIII) functions as a cofactor for factor IXa in the contact coagulation pathway and circulates in a protective complex with von Willebrand factor (VWF).
82	22219226	Plasma FVIII activity is strongly influenced by environmental and genetic factors through VWF-dependent and -independent mechanisms.
83	22219226	Among covariates, age, race, diabetes, and ABO contributed 2.2%, 3.5%, 4%, and 10.7% to FVIII intersubject variation, respectively.
84	22219226	Seven VWF SNPs were associated with FVIII activity in EA subjects, but no FVIII SNPs were associated with VWF Ag.
85	22219226	Factor VIII (FVIII) functions as a cofactor for factor IXa in the contact coagulation pathway and circulates in a protective complex with von Willebrand factor (VWF).
86	22219226	Plasma FVIII activity is strongly influenced by environmental and genetic factors through VWF-dependent and -independent mechanisms.
87	22219226	Among covariates, age, race, diabetes, and ABO contributed 2.2%, 3.5%, 4%, and 10.7% to FVIII intersubject variation, respectively.
88	22219226	Seven VWF SNPs were associated with FVIII activity in EA subjects, but no FVIII SNPs were associated with VWF Ag.